StreetInsider.com News Articles

Form 8-K bioAffinity Technologies For: Oct 15

Thu, 15 Oct 2026 09:30:00 -0400

si-local-file:///var/storage/secattach/20261015/27191125.html

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

Thu, 15 Oct 2026 08:00:00 -0400

Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung

Presentation to address current challenges in pulmonary nodule management and to discuss preliminary research data from the ongoing development of a new, investigational test for asthma and COPD

bioAffinity Technologies' Medical and Scientific Advisory Board to convene in conjunction with CHEST 2026

SAN ANTONIO, Texas--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, will sponsor a Learning Theater presentation at

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

Thu, 15 Oct 2026 08:00:00 -0400

Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung

bioAffinity Technologies' Medical and Scientific Advisory Board to convene in conjunction with CHEST 2026

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

Thu, 15 Oct 2026 08:00:00 -0400

Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung

bioAffinity Technologies' Medical and Scientific Advisory Board to convene in conjunction with CHEST 2026

bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026

Thu, 15 Oct 2026 08:00:00 -0400

Chief Medical Officer Gordon Downie, MD, to host CHEST 2026 Learning Theater on clinical use of CyPath® Lung

bioAffinity Technologies' Medical and Scientific Advisory Board to convene in conjunction with CHEST 2026

Form 8-K bioAffinity Technologies For: Oct 13

Tue, 13 Oct 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20261013/27178782.html

Form PRER14A bioAffinity Technologies

Tue, 13 Oct 2026 06:09:00 -0400

si-local-file:///var/storage/secattach/20261013/27176391.html

Form 8-K bioAffinity Technologies For: Oct 08

Fri, 09 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261009/27171884.html

bioAffinity Technologies closes $4M stock offering on Nasdaq

Fri, 09 Oct 2026 12:30:16 -0400

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) has closed a registered direct offering of common stock and a concurrent private placement, raising approximately $4 million in gross proceeds before placement agent fees and other expenses, according to a press release from WallachBeth Capital LLC.

The shares were sold to an institutional investor at a purchase price of $6.122 per share, or $6.115 per pre-funded warrant, priced at-the-market under Nasdaq rules. The concurrent private placement included warrants to purchase up to 980,072 shares of common stock at an exercise price of $6.122 per share. The pre-funded warrants carry an exercise price of $0.007

bioAffinity Technologies closes $4M stock offering on Nasdaq

Fri, 09 Oct 2026 12:30:16 -0400

WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules